KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Interest & Investment Income (2016 - 2017)

TherapeuticsMD (TXMD) has disclosed Interest & Investment Income for 4 consecutive years, with $3832.0 as the latest value for Q2 2017.

  • For the quarter ending Q2 2017, Interest & Investment Income rose 33.85% year-over-year to $3832.0, compared with a TTM value of $13098.0 through Jun 2017, down 49.99%, and an annual FY2016 reading of $10824.0, down 37.94% over the prior year.
  • Interest & Investment Income was $3832.0 for Q2 2017 at TherapeuticsMD, down from $3867.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $18513.0 in Q1 2015 and bottomed at $2280.0 in Q4 2015.
  • Average Interest & Investment Income over 4 years is $6179.3, with a median of $3832.0 recorded in 2017.
  • The sharpest move saw Interest & Investment Income plummeted 86.3% in 2016, then soared 52.48% in 2017.
  • Year by year, Interest & Investment Income stood at $9364.0 in 2014, then tumbled by 75.65% to $2280.0 in 2015, then grew by 25.57% to $2863.0 in 2016, then soared by 33.85% to $3832.0 in 2017.
  • Business Quant data shows Interest & Investment Income for TXMD at $3832.0 in Q2 2017, $3867.0 in Q1 2017, and $2863.0 in Q2 2016.